Prevalence of and risk factors for low bone mineral density in untreated HIV infection: A substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

HIV Medicine

Volumn 16, Issue S1, 2015, Pages 137-146

  Carr, A ^a   Grund, B ^b   Neuhaus, J ^b   Schwartz, A ^c   Bernardino, Ji ^d   White, D ^e   Badel Faesen, S ^f   Avihingsanon, A ^g,h   Ensrud, K ^b   Hoy, J ⁱ  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^h CHULALONGKORN UNIVERSITY   (Thailand)

ⁱ MONASH UNIVERSITY   (Australia)

Author keywords

Antiretroviral therapy; ART na ve; Bone mineral density; HIV

Indexed keywords

CALCIUM; RETINOL; VITAMIN D;

ADULT; ALCOHOLIC BEVERAGE; ARTICLE; ASIA; ASSOCIATION; BODY MASS; BONE DENSITY; CD4 LYMPHOCYTE COUNT; DEMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTIMATED GLOMERULUS FILTRATION RATE; ETHNICITY; FEMALE; FEMUR NECK; GLOMERULUS FILTRATION RATE; HIP; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SOUTH AMERICA; VIRUS LOAD; VITAMIN SUPPLEMENTATION; COMPLICATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; IMMUNOLOGY; LUMBOSACRAL REGION; MIDDLE AGED; PATHOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SPINE;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIP; HIV INFECTIONS; HUMANS; LUMBOSACRAL REGION; MALE; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE; RISK FACTORS; SPINE;

EID: 84923331145     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12242     Document Type: Article

References (37)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 2165-2174.
2. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metabol 2008; 93: 3499-3504.
3. Dong HV, Cortes YI, Shiau S, Yin MT. Osteoporosis and fractures in HIV/hepatitis C virus coinfection: a systematic review and meta-analysis. AIDS 2014; 28: 2119-2131.
4. Bolland MJ, Grey AB, Gamble GD, Reid IR. CLINICAL Review # : low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metabol 2007; 92: 4522-4528.
5. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21: 617-623.
6. Yin MT, Zhang CA, McMahon DJ etal. Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metabol 2012; 97: 554-562.
7. Hoy J. Bone, fracture and frailty. Curr Opin HIV AIDS 2011; 6: 309-314.
8. Gallant JE, Staszewski S, Pozniak AL etal. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
9. Stellbrink HJ, Orkin C, Arribas JR etal. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51: 963-972.
10. McComsey GA, Kitch D, Daar ES etal. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203: 1791-1801.
11. Ofotokun I, McIntosh E, Weitzmann MN. HIV: inflammation and bone. Curr HIV/AIDS Rep 2012; 9: 16-25.
12. Grant PM, Kitch D, McComsey GA etal. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 2013; 57: 1483-1488.
13. Cotter EJ, Malizia AP, Chew N, Powderly WG, Doran PP. HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses 2007; 23: 1521-1530.
14. Gibellini D, De Crignis E, Ponti C etal. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008; 80: 1507-1514.
15. Gibellini D, Borderi M, De Crignis E etal. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol 2007; 79: 1446-1454.
16. Vikulina T, Fan X, Yamaguchi M etal. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci USA 2010; 107: 13848-13853.
17. Kamen DL, Alele JD. Skeletal manifestations of systemic autoimmune diseases. Curr Opin Endocrinol Diabetes Obes 2010; 17: 540-545.
18. Hardy R, Cooper MS. Bone loss in inflammatory disorders. J Endocrinol 2009; 201: 309-320.
19. Hileman CO, Labbato DE, Storer NJ, Tangpricha V, McComsey GA. Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. AIDS 2014; 28: 1759-1767.
20. Libois A, Clumeck N, Kabeya K etal. Risk factors of osteopenia in HIV-infected women: no role of antiretroviral therapy. Maturitas 2010; 65: 51-54.
21. Brown TT, Chen Y, Currier JS etal. Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2013; 63: 323-330.
22. Masyeni S, Utama S, Somia A, Widiana R, Merati TP. Factors influencing bone mineral density in ARV-naive patients at Sanglah Hospital, Bali. Acta Med Indones 2013; 45: 175-179.
23. Hamill MM, Ward KA, Pettifor JM, Norris SA, Prentice A. Bone mass, body composition and vitamin D status of ARV-naive, urban, black South African women with HIV infection, stratified by CD(4) count. Osteoporosis Int 2013; 24: 2855-2861.
24. Grijsen ML, Vrouenraets SM, Steingrover R etal. High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS 2010; 24: 2233-2238.
25. Babiker AG, Emery S, Fatkenheuer G etal. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013; 10: S5-S36.
26. Lu Y, Fuerst T, Hui S, Genant HK. Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporosis Int 2001; 12: 438-444.
27. Hui SL, Gao S, Zhou XH etal. Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res 1997; 12: 1463-1470.
28. Looker AC, Borrud LG, Hughes JP, Fan B, Shepherd JA, Melton LJ, 3rd. Lumbar spine and proximal femur bone mineral density, bone mineral content, and bone area: United States, 2005-2008. Vital Health Stat 11 2012; 251: 1-132.
29. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom 2013; 16: 455-466.
30. Cosman F, de Beur SJ, LeBoff MS etal. Clinician's guide to prevention and treatment of osteoporosis. Osteoporosis Int 2014; 25: 2359-2381.
31. Harrell FE. Regression Modeling Strategies: With Application to Linear Models, Logistic Regression and Survival Analysis. New York, Springer, 2001.
32. National Institute of Alcohol Abuse and Alcoholism. USA: National Institutes of Health, US Department of Health and Human Services; 2014. Available at http://www.niaaa.nih.gov/alcohol-your-health/overview-alcohol-consumption/moderate-binge-drinking (accessed 15 September 2014).
33. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
34. Shiau S, Broun EC, Arpadi SM, Yin MT. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS 2013; 27: 1949-1957.
35. Cotter AG, Sabin CA, Simelane S etal. Relative contribution of HIV infection, demographics and body mass index to bone mineral density. AIDS 2014; 28: 2051-2060.
36. Kooij KW, Wit FW, Bisschop PH etal. Low bone mineral density in patients with well-suppressed HIV infection is largely explained by body weight, smoking and prior advanced HIV disease. J Infect Dis 2014 Sep 1. pii: jiu499. [Epub ahead of print].
37. INSIGHT START Study Group. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med 2015; 16 (Suppl 1): 1-9.